NCT00226330终止3 期
A Double-Blind, Multi-Centre, Active-Controlled (15, 30, and 45 mg Pioglitazone) Long-Term Extension Study to Evaluate the Safety and Tolerability of Tesaglitazar (0.5 and 1 mg) in Patients With Type 2 Diabetes Mellitus (GALLEX 6)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- AstraZeneca
- 入组人数
- 1,100
- 试验地点
- 170
- 主要终点
- Adverse events
研究概览
简要总结
This is a parallel-group, multi-center, long-term extension study from the GALLANT 6 study to monitor the safety and tolerability of oral tesaglitazar compared with pioglitazone in patients with type 2 diabetes for up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of a written informed consent
- •Men or women who are >= 18 years of age
- •Female patients: postmenopausal; hysterectomized; or, if of childbearing potential, using a reliable method of birth control.
- •Completed the last two visits of the randomized treatment period in GALLANT 6
排除标准
- •Type 1 diabetes
- •New York Heart Association heart failure Class III or IV
- •Treatment with chronic insulin
- •History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)
- •History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, or neutropenia (low white blood cells)
- •Creatinine levels of above twice the normal range
- •Creatine kinase of above 3 times the upper limit of normal
- •Previous enrollment in this long-term extension study
- •Any clinically significant abnormality identified by physical examination, laboratory tests or electrocardiogram, which, in the judgment of the investigator, would compromise the patient's safety or successful participation in the clinical study
结局指标
主要结局
Adverse events
Laboratory variables
Physical examination
Cardiac evaluation
Hypoglycemic events
Electrocardiogram
Vital signs (blood pressure and pulse)
Body weight
次要结局
- Pharmacodynamic: fasting plasma glucose, glycosylated hemoglobin A1c
- Lipid variables (triglyceride, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol [HDL-C], and non-HDL-C)
- Responder rates and proportion of patients on tesaglitazar who reach pre-specified target levels for triglyceride, total cholesterol, low-density lipoprotein cholesterol, HDL-C and non-HDL-C
- C-reactive protein (CRP)
- Central obesity (waist circumference, hip circumference, waist/hip ratio)
- Patient reported outcomes using the Medical Outcomes Study Short Form-36 (SF-36)
研究者
研究点 (170)
Loading locations...
相似试验
终止
3 期
GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 DiabetesType 2 DiabetesNCT00300105AstraZeneca400
终止
3 期
GALLEX 1 - Long Term Extension Study in Patients With Type 2 DiabetesType 2 DiabetesNCT00252876AstraZeneca2,000
已完成
2 期
Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020SchizophreniaNCT00722176BioLineRx, Ltd.220
已完成
3 期
Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®COPDNCT03262012Pearl Therapeutics, Inc.416
终止
3 期
GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00229710AstraZeneca270